Goldman Sachs
PRTK

Goldman Sachs’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Goldman Sachs’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-75,000
Closed -$1.88M – 6737
2017
Q3 		$1.88M Buy
+75,000
New +$1.75M ﹤0.01% 4058
2017
Q2 		– Sell
-50,000
Closed -$963K – 7035
2017
Q1 		$963K Buy
+50,000
New +$788K ﹤0.01% 4412

Other funds holding PRTK

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Goldman Sachs's PRTK Position: Q2 2023 in Review

Goldman Sachs sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 36,773 shares — an estimated $93.4K sold.

Goldman Sachs first reported a position in PRTK in Q2 2013 and held it in 31 quarters. The position peaked at $3.17M in Q2 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

  • Goldman Sachs reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Goldman Sachs sold 36,773 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $93.4K.
  • Goldman Sachs first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
  • Goldman Sachs's Paratek Pharmaceuticals, Inc. position peaked at $3.17M in Q2 2017.
  • 66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Goldman Sachs's 13F filing for Q2 2023, filed 15 Aug 2023.